Bifogade filer
AcouSort extends collaboration with leading cell therapy company into a third project phase
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
AcouSort’s collaboration with the global life science company has reached yet another significant milestone with the signing of a Statement of Work (SoW) describing Phase 3 in the ongoing collaboration. The new assignment will generate revenues of at least SEK 485,000 in 2024.
The collaboration, which began in 2022, aims to demonstrate how AcouSort’s AcouWash technology can be adapted for industrial use and integrated as OEM components to automate certain processing steps in the partnering company’s future cell therapy products and instruments. The feedback from the partnering company has been positive throughout the collaboration and in the now agreed phase 3, AcouSort will optimize and expand its technology so that it can be used in all relevant steps of cell therapy production processes.
“With the positive feedback we have received throughout the collaboration, the signing of the SoW comes as no surprise, but is still extremely gratifying. AcouSort will now take another step forwards within this strategically important partnership with the ambition to ultimately establish profitable sales of disposable OEM components. We could not have wished for a better start to the year,” says Torsten Freltoft, AcouSort’s CEO.